Oncolytics Biotech (ONCY +3.2%) says interim data from Phase 2 clinical trials using intravenous...

|By:, SA News Editor

Oncolytics Biotech (ONCY +3.2%) says interim data from Phase 2 clinical trials using intravenous administration of Reolysin in combination with Gemzar in patients with advanced pancreatic cancer was successful in reaching its primary endpoint.